To Cite:
Yahyapour
Y, Aghajanipour
K, Mir
S M, Khademian
A, Sadeghi
F. Human T- Lymphotropic Virus Type 1 in Blood Donors from Babol County Blood Transfusion Center: A Pilot Study From Northern Iran,
Jundishapur J Microbiol.
2017
; 10(9):e13757.
doi: 10.5812/jjm.13757.
1.
Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016; 4(9)-16[DOI][PubMed]
2.
Gessain A, Cassar O. Epidemiological Aspects and World Distribution of HTLV-1 Infection. Front Microbiol. 2012; 3: 388[DOI][PubMed]
3.
Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005; 24(39): 6058-68[DOI][PubMed]
4.
Goncalves DU,
Proietti FA,
Ribas JG,
Araujo MG,
Pinheiro SR,
Guedes AC,
et al.
Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev. 2010; 23(3): 577-89[DOI][PubMed]
5.
Chang YB,
Kaidarova Z,
Hindes D,
Bravo M,
Kiely N,
Kamel H,
et al.
Seroprevalence and demographic determinants of human T-lymphotropic virus type 1 and 2 infections among first-time blood donors--United States, 2000-2009. J Infect Dis. 2014; 209(4): 523-31[DOI][PubMed]
6.
Rafatpanah H,
Hedayati-Moghaddam MR,
Fathimoghadam F,
Bidkhori HR,
Shamsian SK,
Ahmadi S,
et al.
High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J Clin Virol. 2011; 52(3): 172-6[DOI][PubMed]
7.
Hedayati-Moghaddam MR, Tehranian F, Bayati M. Human T-Lymphotropic Virus Type I (HTLV-1) Infection among Iranian Blood Donors: First Case-Control Study on the Risk Factors. Viruses. 2015; 7(11): 5736-45[DOI][PubMed]
8.
Hedayati-Moghaddam MR. A Systematic Review for Estimation of HTLV-I Infection in the Blood Donors of Iran. Iran J Basic Med Sci. 2013; 16(3): 196-201[PubMed]
9.
Sadeghi F,
Bokharaei-Salim F,
Salehi-Vaziri M,
Monavari SH,
Alavian SM,
Salimi S,
et al.
Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNalpha-2a and ribavirin in Iranian patients with chronic hepatitis C. J Med Virol. 2014; 86(9): 1499-506[DOI][PubMed]
10.
Salehi-Vaziri M, Sadeghi F, Alamsi-Hashiani A, Haeri H, Monavari SH, Keyvani H. Merkel cell polyomavirus and human papillomavirus infections in cervical disease in Iranian women. Arch Virol. 2015; 160(5): 1181-7[DOI][PubMed]
11.
Naderi M, Paryan M, Azadmanesh K, Rafatpanah H, Rezvan H, Mirab Samiee S. Design and development of a quantitative real time PCR assay for monitoring of HTLV-1 provirus in whole blood. J Clin Virol. 2012; 53(4): 302-7[DOI][PubMed]
12.
Hedayati-Moghaddam MR, Fathimoghadam F, Eftekharzadeh Mashhadi I, Soghandi L, Bidkhori HR. Epidemiology of HTLV-1 in Neyshabour, Northeast of Iran. Iran Red Crescent Med J. 2011; 13(6): 424-7[PubMed]
13.
Azarpazhooh MR,
Hasanpour K,
Ghanbari M,
Rezaee SA,
Mashkani B,
Hedayati-Moghaddam MR,
et al.
Human T-lymphotropic virus type 1 prevalence in northeastern Iran, Sabzevar: an epidemiologic-based study and phylogenetic analysis. AIDS Res Hum Retroviruses. 2012; 28(9): 1095-101[DOI][PubMed]
14.
Khameneh ZR, Baradaran M, Sepehrvand N. Survey of the seroprovalence of HTLV I/II in hemodialysis patients and blood donors in Urmia. Saudi J Kidney Dis Transpl. 2008; 19(5): 838-41[PubMed]
15.
Rafatpanah H,
Torkamani M,
Valizadeh N,
Vakili R,
Meshkani B,
Khademi H,
et al.
Prevalence and phylogenetic analysis of HTLV-1 in a segregated population in Iran. J Med Virol. 2016; 88(7): 1247-53[DOI][PubMed]
16.
Ajami A, Hosseini RF, Tabarestani N. Seroepidemiological survey of HTLV-I/II in blood donors of Mazandaran in 1999 [In Persian]. J Mazandaran Univ Med Sci. 2000; 10(26): 45-8
17.
Ghaffari J, Kowsarian M, Mahdavi M, Vahid Shahi K, Rafatpanah H, Tafreshian A. Prevalence of HTLV-I infection in patients with thalassemia major in Mazandaran, North of Iran. Jundishapur J Microbiol. 2012; 6(1): 57-60[DOI]
Readers' Comments